CANAGLIFLOZIN ANHYDROUS
Small molecule targets SLC5A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 16 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed chronic kidney disease 1 milestone | |||||
| Filed | US (FDA) | INVOKANA | chronic kidney disease | 2019-03-28 | “Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes” jnj.com ↗ “basis for Janssen’s March 2019 filing of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for INVOKANA®” jnj.com ↗ “InMarch 2019, Janssen included the CREDENCE data in the submission of a supplemental New Drug Application to the U.S. FDA for INVOKANA®” jnj.com ↗ “In March 2019, Janssen submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for INVOKANA®” jnj.com ↗ |
| Filed type 2 diabetes mellitus 6 milestones | |||||
| Rejected (CRL) | US (FDA) | — | type 2 diabetes mellitus | 2013-12-12 | “FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed -Dose Combination Therapy for Type 2 Diabetes” jnj.com ↗ |
| Filed | Japan (PMDA) | — | type 2 diabetes mellitus | 2013-05-27 | “New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes” tanabe-pharma.com ↗ |
| Filed | EU (EMA) | — | type 2 diabetes mellitus | 2013-03-07 | “Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes” jnj.com ↗ |
| Filed | US (FDA) | — | type 2 diabetes mellitus | 2012-12-12 | “Janssen announced the submission of the canagliflozin/metformin fixed-dose combination therapy NDA on December 12, 2012.” jnj.com ↗ |
| Filed | EU (EMA) | — | type 2 diabetes mellitus | 2012-06-26 | “included in the MAA for canagliflozin submitted to the EMA on 26 June 2012” jnj.com ↗ |
| Filed | US (FDA) | — | type 2 diabetes mellitus | 2012-05-31 | “the New Drug Application (NDA) for canagliflozin that was submitted by Janssen on May 31, 2012” jnj.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (7) | US (FDA) | INVOKANA | — | 2015-09-10 – 2024-12-18 | fda.gov ↗ |
| Approved | EU (EMA) | Invokana | — | 2013-11-15 | europa.eu ↗ |
| Approved | US (FDA) | INVOKANA | — | 2013-03-29 | fda.gov ↗ |
Trials 112 · started per year
News releases announcing trial results or a regulatory action · 37
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | Tanabe Pharma Corporation | Regulatory Regulatory Approval of CANALIA® Tablets, type 2 diabetes mellitus treatment agent in Thailand tanabe-pharma.com ↗
Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada; hereinafter "Tanabe Pharma") announced today that on June 24th, 2026, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd. (hereinafter “MTTH”) received Marketing Authorization for CANALIA® Tablets, a type 2 diabetes mellitus treatment agent that combines selective DPP-4 inhibitor TENELIA® Tablets (generic name: teneligliptin) and SGLT2 inhibitor CANAGLU® Tablets (generic name: canagliflozin) in Thailand. |
| 2024-03-18 | Tanabe Pharma Corporation | Regulatory Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets～First OD Tablets of SGLT2 inhibitors in Japan～ tanabe-pharma.com ↗
CANAGLU® OD T ablet is the first SGLT2 inhibitor OD tablet approved in Japan. |
| 2024-02-20 | Tanabe Pharma Corporation | Regulatory Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug tanabe-pharma.com ↗
Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug |
| 2023-11-23 | Lupin Limited | Regulatory Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets lupin.com ↗ |
| 2023-02-15 | Zydus Lifesciences Limited | Regulatory Zydus receives tentative approval from the USFDA for Canagliflozin Tablets zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg (USRLD: Invokana® Tablets). |
| 2021-02-26 | Tanabe Pharma Corporation | Regulatory Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy tanabe-pharma.com ↗
obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA on February 1, 2021. |
| 2020-07-01 | Mundipharma Research Limited | Regulatory European Commission approves extended Invokana® (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes seen in CREDENCE study mundipharma.com ↗
Invokana® (canagliflozin) is now the only sodium glucose co-transporter 2 inhibitor (SGLT2i) approved in Europe with an extended indication to treat diabetic kidney disease (DKD) in type 2 diabetes (T2DM) patients. |
| 2019-11-12 | Janssen Research & Development, LLC | Results New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function jnj.com ↗
This analysis showed that INVOKANA®provides a strong, consistent safety profile and efficacy at all tested eGFR levels. |
| 2019-09-30 | Janssen Research & Development, LLC | Regulatory U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD jnj.com ↗
INVOKANA®is now the only type 2 diabetes medicine indicated to both treat diabetic kidney disease and reduce the risk of hospitalization for heart failure in patients with T2D and DKD. |
| 2019-09-30 | Janssen Research & Development, LLC | Regulatory U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD jnj.com ↗
INVOKANA® is now the only type 2 diabetes medicine indicated to both treat diabetic kidney disease and reduce the risk of hospitalization for heart failure in patients with T2D and DKD. |
| 2019-06-11 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis jnj.com ↗ |
| 2019-05-22 | Janssen Research & Development, LLC | Regulatory U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes jnj.com ↗ |
| 2019-05-22 | Janssen Research & Development, LLC | Regulatory U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes jnj.com ↗
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes |
| 2019-04-15 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study jnj.com ↗
In the study, INVOKANA®significantly reduced the combined risk of cardiovascular death, myocardial infarction, and stroke, and demonstrated no imbalance in amputation or bone fracture |
| 2019-04-14 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study jnj.com ↗
INVOKANA® is the only medicine in nearly 20 years and the first diabetes medicine to demonstrate significant reduction in risk of renal failure, dialysis or kidney transplantation, and renal or cardiovascular death in this high-risk patient population |
| 2019-03-28 | Janssen Research & Development, LLC | Regulatory Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes jnj.com ↗ |
| 2019-03-28 | Janssen Research & Development, LLC | Regulatory Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes jnj.com ↗
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes |
| 2018-10-30 | Janssen Research & Development, LLC | Regulatory U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved INVOKANA® (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events, including heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease. |
| 2018-07-16 | Janssen Research & Development, LLC | Results Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings jnj.com ↗
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings |
| 2018-04-12 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease jnj.com ↗
In the new analysis, canagliflozin reduced the urinary albumin to creatinine ratio (UACR), a key biomarker for chronic kidney disease, from baseline eGFR in patients with preserved and reduced eGFR by 17 percent and 23 percent, respectively (P-heterogeneity=0.01). |
| 2018-03-11 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease jnj.com ↗
“This new analysis from the CANVAS Program demonstrates that canagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure," said Javed Butler, M.D., M.P.H., Chairman of Medicine at University of Mississippi. |
| 2017-11-20 | Janssen Research & Development, LLC | Results New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines jnj.com ↗
EASEL is the first real-world study to show adults with type 2 diabetes and established cardiovascular disease (CVD) have a lower risk of major adverse cardiovascular events (MACE) with SGLT2i therapy |
| 2017-11-14 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events jnj.com ↗
Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA® (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV disease. |
| 2017-11-03 | Janssen Research & Development, LLC | Results INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease jnj.com ↗
The renal analyses showed that compared to placebo, canagliflozin reduced the risk of kidney disease progression, including significantly reducing urinary albumin excretion and stabilizing estimated glomerular filtration rate (eGFR) over a study duration of more than six years: |
| 2017-10-02 | Janssen Research & Development, LLC | Regulatory Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program jnj.com ↗
Janssen Research & Development, LLC (Janssen) announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for INVOKANA® (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE), composed of cardiovascular (CV) death, myocardial infarction and stroke, in adults with type 2 diabetes who have established CV disease or are at risk for CV disease. |
| 2016-03-14 | Janssen Research & Development, LLC | Results First Real-World Evidence Comparing an SGLT2 Inhibitor with DPP-4 Inhibitors Shows Adults with Type 2 Diabetes Achieve Greater Blood Glucose Control with INVOKANA® (canagliflozin) jnj.com ↗ |
| 2015-11-20 | Janssen Research & Development, LLC | Regulatory Janssen Submits INVOKAMET® XR (Canagliflozin / Metformin Hydrochloride Extended Release) for Approval by the U.S. FDA as an Adjunctive Treatment in Adults with Type 2 Diabetes jnj.com ↗ |
| 2014-07-04 | Daiichi Sankyo | Regulatory Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg daiichisankyo.com ↗ |
| 2014-04-25 | Janssen Research & Development, LLC | Regulatory VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) approved in the European Union for treatment of adults with type 2 diabetes [1] jnj.com ↗
VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) approved in the European Union for treatment of adults with type 2 diabetes |
| 2014-02-21 | Janssen Research & Development, LLC | Regulatory VOKANAMET® (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1] jnj.com ↗
VOKANAMET™ (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1] |
| 2013-11-22 | Janssen Research & Development, LLC | Regulatory INVOKANA™ (canagliflozin) APPROVED IN THE EUROPEAN UNION FOR TREATMENT OF ADULTS WITH TYPE 2 DIABETES1 jnj.com ↗
Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved INVOKANA™ (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control [1]. |
| 2013-09-20 | Janssen Research & Development, LLC | Regulatory Invokana® (Canagliflozin) Receives Positive Opinion Recommending Approval in the European Union for the Treatment of Adults with Type 2 Diabetes Mellitus1 jnj.com ↗
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion recommending approval of INVOKANA® (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control. |
| 2013-06-23 | Janssen Research & Development, LLC | Results Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes jnj.com ↗
The study also showed that 100 mg of INVOKANA™ provided similar improvements in blood glucose control to sitagliptin, and both doses of INVOKANA™ resulted in greater secondary endpoint reductions in body weight and blood pressure. |
| 2013-05-27 | Tanabe Pharma Corporation | Regulatory New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes tanabe-pharma.com ↗
New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes |
| 2013-03-29 | Janssen Research & Development, LLC | Regulatory U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes jnj.com ↗
Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the treatment of adults with type 2 diabetes. |
| 2013-03-07 | Janssen Research & Development, LLC | Regulatory Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes jnj.com ↗
Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes |
| 2013-01-10 | Janssen Research & Development, LLC | Regulatory FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes jnj.com ↗
FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes |
All press releases naming this drug 40 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 144 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANAGLIFLOZIN ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | 28431754 | “A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers” NCT01173549 ↗1“A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers” NCT01157000 ↗ |
| Known as | CANA | “The purpose of this study is to assess the effect of coadministration of a high-fat meal on the oral bioavailability of a fixed dose combination of Canagliflozin/extended...” NCT02039258 ↗3“Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated” PMID 36147577 ↗ Sep 2022 “canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.” PMID 32220916 ↗ Mar 2020 “canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor” PMID 26786577 ↗ Jan 2016 |
| Known as | Canagliflozin | “A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of...” NCT02039258 ↗130“To assess the effect of food on the pharmacokinetics (PK) of canagliflozin and metformin following administration of a canagliflozin/metformin (150/1,000 mg) immediate-release...” PMID 25546166 ↗ Mar 2015 “Canagliflozin is an orally active, selective, reversible sodium-glucose cotransport-2 (SGLT-2) inhibitor used in patients with chronic kidney disease (CKD) to prevent...” PMID 40952584 ↗ Sep 2025 “This study is designed to mitigate the effects of glucose with intermittent oral Canagliflozin for healthy, non-diabetic volunteers of any sex who enroll in the study.” NCT06301529 ↗ “Intervention: Dapagliflozine 10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment.” NCT04127084 ↗ “This review summarizes data on the effect of SGLT2 inhibitors marketed in the US (namely canagliflozin, dapagliflozin, or empagliflozin) on BP in patients with T2DM.” PMID 27822054 ↗ Oct 2016 “Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors” NCT06449235 ↗ “Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)” NCT02039245 ↗ “receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin)” NCT04419337 ↗ “Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required” NCT04196231 ↗ “SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD” NCT07391267 ↗ |
| Known as | canagliflozin (Invokana) | “canagliflozin (Invokana®)” NCT07325435 ↗ |
| Known as | Canagliflozin component of invokamet | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozin hemihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Canagliflozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | Invokana | “A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™...” NCT01916863 ↗3“Invokana (Canagliflozin) might act as a potent dual inhibitor of AChE and SGLT2.” NCT04304261 ↗ “Canagliflozin (Invokana) 300 mg tablet” NCT06182839 ↗ |
| Known as | Invokana (brand name for canagliflozin) | “Invokana (brand name for canagliflozin)” NCT02891954 ↗ |
| Known as | InvokanaTM | “Canagliflozin (sold as InvokanaTM) is a new medicine for diabetes.” NCT02404870 ↗ |
| Known as | JNJ-24831754 | “A Study of the Effects of Canagliflozin [JNJ-24831754] on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)” PMID 36302584 ↗ Nov 2022 |
| Known as | JNJ-24831754-ZAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | JNJ-28431754 | “The purpose of this study is to investigate the absorption (the way the drug enters the body), metabolism (the way the drug is broken down in the body), and excretion (the way...” NCT01791231 ↗21“An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an...” NCT01157000 ↗ “An Open-Label Drug Interaction Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Administered Alone and in Combination With Multiple-Dose JNJ-28431754...” NCT01195324 ↗ “A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose...” NCT01173549 ↗ “A Double-Blind, Placebo-Controlled, Randomized, Parallel-Groups Study to Investigate the Effects of JNJ-28431754 (Canagliflozin) on Plasma Volume and Renal Function in Subjects...” NCT01483781 ↗ “This is an open-label (volunteers and study staff will know the name and dose of the treatment assigned), single-center study of canagliflozin (JNJ-28431754) in healthy adult...” NCT01281579 ↗ “The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM)” NCT02025907 ↗ “This is an open-label (volunteers will know the names of treatments they are assigned), single-center study of canagliflozin (JNJ-28431754) in healthy adult volunteers.” NCT01286103 ↗ “Canagliflozin (also referred to as JNJ-28431754) is a drug that is being tested to see if it may be useful in treating patients diagnosed with T2DM.” NCT01064414 ↗ “Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.” NCT00968812 ↗ “The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo” NCT01939496 ↗ |
| Known as | JNJ-28431754-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2048484 ↗ |
| Known as | TA-7284 | “Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus” NCT02220920 ↗ |
| Action | Inhibit | “canagliflozin, a sodium glucose co-transporter 2 inhibitor” PMID 22632452 ↗ Jun 20121“Sodium/glucose cotransporter 2 inhibitor” CHEMBL2048484 ↗ |
| Modality | Small molecule | — CHEMBL2048484 ↗ |
| Route | Oral | “One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks” NCT00642278 ↗ |
| Target | SLC5A2 | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL2048484 ↗ |